Program/TargetProg/Tgt
IndicationInd
DiscoveryDiscov
Lead
Optimization
Lead Opt
IND
Enabling
IND
Phase 1Ph 1
Phase 2Ph 2
CollaborationsCollab
OKI-179
NRAS Melanoma(1)
OKI-179
Oral, Selective Class I HDAC inhibitor
NRAS Melanoma(1)
In combination w/ binimetinib
Nautilus Trial
Pfizer logo
Class I HDAC inhibition has been shown to dramatically enhance the efficacy of MEK inhibitors in Ras pathway driven melanomas by coordinately suppressing two DNA repair pathways. A potential clinical biomarker that predicts responsiveness has also been identified.
OKI-DISC-1
Undisclosed
OKI-DISC-1
Oncogenic Signaling Kinase Inhibitor
Undisclosed
OKI-DISC-2
Undisclosed
OKI-DISC-2
Mutant Selective Oncogenic RTK
Undisclosed
OKI-DISC-3
Undisclosed
OKI-DISC-3
Oncogenic Signaling Kinase Inhibitor
Undisclosed

(1) OKI-179 Phase 1 FIH single agent trial previously completed.

(2) Pursuant to a Clinical Trial Collaboration and Supply Agreement with Pfizer for binimetinib/OKI-179 combination; OnKure retains all OKI-179 commercial rights.